Oral Administration of GnRH Antagonist Acyline Effectively Suppresses Testosterone in Men

Strategic Insights -

A team of researchers from the University of Washington has made a significant breakthrough in the treatment of prostate cancer by developing an orally bioavailable form of the GnRH antagonist acyline. The findings, published in Cancer Chemotherapy and Pharmacology, demonstrate that oral administration of GIPET(A [R])-enhanced acyline can safely and effectively suppress testosterone levels in healthy young men for an extended period.

Key Takeaways:

  • The researchers enrolled eight healthy young men in a pharmacokinetic and pharmacodynamic study to evaluate the safety and efficacy of oral GIPET(A [R])-enhanced acyline.
  • The study found that all doses of GIPET(A [R])-enhanced oral acyline significantly suppressed serum testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) after 6 h, with suppression reaching a nadir 12 h after dosing.
  • The 20 and 40 mg doses of GIPET(A [R])-enhanced oral acyline demonstrated sustained suppression of testosterone for 12-24 h.
  • No treatment-related serious adverse events were reported, and laboratory assessments showed no changes in liver function tests or creatinine levels.
  • The study's findings suggest that oral administration of GIPET(A [R])-enhanced acyline may have utility in the management of prostate cancer.

Statistics:

  • Eight healthy young men were enrolled in the pharmacokinetic and pharmacodynamic study.
  • The study evaluated three different doses of GIPET(A [R])-enhanced oral acyline: 10, 20, and 40 mg.
  • Serum testosterone levels were significantly suppressed by all doses of GIPET(A [R])-enhanced oral acyline after 6 h (p < 0.0001).
  • The nadir suppression of testosterone was reached 12 h after dosing (p < 0.0001).
  • The 20 and 40 mg doses of GIPET(A [R])-enhanced oral acyline demonstrated sustained suppression of testosterone for 12-24 h (p < 0.01).
  • No treatment-related serious adverse events were reported in the study.

Sources:

  • Amory, J.K., et al. (2009). Oral administration of the GnRH antagonist acyline, in a GIPET(A[R])-enhanced tablet form, acutely suppresses serum testosterone in normal men: single-dose pharmacokinetics and pharmacodynamics. Cancer Chemotherapy and Pharmacology, 64(3), 641-645.